Physician profile
Dal Yoo
NPI 1063564532
$5,935.54
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,287 · 2020: $293 · 2021: $124 · 2022: $97.49 · 2024: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $2,611.93 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $778.05 | 2019-2020 | |
| Janssen Biotech, INC. | $314.64 | 2019-2020 | |
| Celgene Corporation | $312.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $280.85 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $165.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.80 | 2019-2020 | |
| Dexcom, INC. | $134.07 | 2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $124.06 | 2021 | |
| Abbvie INC. | $109.75 | 2019 | |
| Daiichi Sankyo INC. | $105.19 | 2019 | |
| Gilead Sciences, INC. | $97.49 | 2022 | |
| Exelixis INC. | $94.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $88.41 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $66.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.87 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $50.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.68 | 2019 | |
| Eisai INC. | $38.58 | 2019-2020 | |
| Pfizer INC. | $33.88 | 2019 | |
| Emd Serono, INC. | $30.09 | 2019 | |
| Genentech USA, INC. | $22.03 | 2019 | |
| Puma Biotechnology, INC. | $21.29 | 2020 | |
| Incyte Corporation | $19.59 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.45 | 2019 | |
| Merck Sharp & Dohme LLC | $15.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dal Yoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.